Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03333057
Study type Interventional
Source Novaliq GmbH
Contact
Status Completed
Phase Phase 2
Start date January 3, 2018
Completion date July 27, 2018

See also
  Status Clinical Trial Phase
Completed NCT04140227 - Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study) Phase 3
Completed NCT04393441 - Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease Phase 3
Completed NCT04036292 - Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease Phase 3
Completed NCT04139798 - Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study) Phase 3
Completed NCT04523142 - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004 Phase 3
Completed NCT01998802 - Phase 3 Study of EBI-005 in Dry Eye Disease Phase 3
Completed NCT05723770 - Effects of NOV03 on the Tear Film Phase 4